Founded in 2018, Megadalton Solutions has developed CDMS instrumentation that makes it possible to analyze extremely large proteins and protein complexes, such as those used in cell and gene therapies, that would otherwise be difficult to analyze with conventional mass spectrometry.

Waters became a strategic investor in Megadalton, and in 2021, brought its CDMS technology into the Waters Immerse Cambridge innovation and research lab for advanced testing and development. Financial details of the transaction were not disclosed.

Waters expands its informatics software platform
Waters has expanded its Waters Connect informatics software platform to support customers analyzing food and environmental samples with Waters' tandem...

Waters, Sartorius to partner on mass spectrometry data
Waters and Sartorius announced that they will partner to provide direct access to mass spectrometry data to improve the accuracy of biopharmaceutical...

Waters, U. of Delaware to collaborate on biopharma processing
Waters and the University of Delaware have initiated a five-year collaboration focused on improving quality, yields, and efficiency in the manufacturing...

Waters introduces new LC-MS system
Lab equipment supplier Waters has introduced the BioAccord system with Acquity Premier, a liquid chromatography-mass spectrometry (LC-MS) system designed...